Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001641172-25-001199
Filing Date
2025-03-28
Accepted
2025-03-28 16:15:31
Documents
68
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 1516531
2 ex31-1.htm EX-31.1 18577
3 ex31-2.htm EX-31.2 19024
4 ex32-1.htm EX-32.1 10610
5 audit_001.jpg GRAPHIC 3901
  Complete submission text file 0001641172-25-001199.txt   5992774

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE impb-20241231.xsd EX-101.SCH 35031
7 XBRL CALCULATION FILE impb-20241231_cal.xml EX-101.CAL 59000
8 XBRL DEFINITION FILE impb-20241231_def.xml EX-101.DEF 145472
9 XBRL LABEL FILE impb-20241231_lab.xml EX-101.LAB 370113
10 XBRL PRESENTATION FILE impb-20241231_pre.xml EX-101.PRE 295790
70 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 740011
Mailing Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084
Business Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084 585 232 1500
IMPACT BIOMEDICAL INC. (Filer) CIK: 0001834105 (see all company filings)

EIN.: 853926944 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-42212 | Film No.: 25786466
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)